FDA Names the Five Peptides Its Advisory Committee Will Review in February 2027
Legal industry coverage of the FDA's April 2026 Federal Register notice confirms the Pharmacy Compounding Advisory Committee (PCAC) — the body that voted in July 2026 to recommend six peptides for the 503A Bulks List — will reconvene by the end of February 2027 to review five additional peptides for compounding eligibility: GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and PEG-MGF (pegylated Mechano Growth Factor). As with the July review, FDA staff will present a scientific evaluation of each substance before the committee votes on a recommendation, and becoming eligible for compounding would not constitute FDA approval or a determination that a peptide is safe or effective for its promoted uses.
This is a summary. The reporting is The FDA Law Blog's, and the link below goes to the original article.